Acadia (ACHC) Q1 2026 Earnings Call Transcript

Acadia Healthcare reported Q1 revenue of $828.8 million, up 7.6%, and adjusted EBITDA of $144.2 million, beating the high end of guidance by $7.2 million. Management raised full-year adjusted EBITDA guidance to $580 million-$615 million and EPS guidance to $1.35-$1.60, supported by strong acute and RTC performance, cost efficiencies, and supplemental payments, though specialty revenue fell 6.5% and bad debt/denials remain a headwind. The quarter also featured leadership restructuring, a lower corporate overhead structure, and early AI pilots in revenue cycle management and care prediction.

Analysis

The key incremental positive is not the headline beat; it is that management is now actively rewiring the operating model while the core demand engine is still accelerating. That combination matters because behavioral-health operators usually get the revenue first and the margin later, but here the company is already harvesting early G&A and labor efficiency before the new-bed cohort is fully ramped. If the acute reorganization and JV-specific oversight work as intended, the earnings mix should shift from payment-dependent volatility toward more durable throughput and per-bed productivity over the next 2-3 quarters.

The market may be underestimating how much of the near-term guide is mechanically inflated by prior-year supplemental timing, which creates a temporary leverage spike and could keep the stock range-bound even as fundamentals improve. That said, the underlying setup is better than it looks: lower capex, improving retention, and a maturing de novo cohort mean free cash flow should inflect faster than EBITDA once the opening-cycle drag peaks. The big second-order winner is not just ACHC’s equity; it is the balance sheet optionality to selectively accelerate openings or acquisitions once leverage normalizes.

The main risk is that revenue-cycle deterioration could offset a meaningful piece of the operating leverage, and this is the part to watch as the easiest margin lever to lose control of. Because payer pushback is broad-based rather than isolated, it can persist for several quarters and show up first in AR days, cash conversion, and guidance credibility before it hits reported revenue. A colder read is that the stock may be overreacting to the beat if investors extrapolate supplemental-driven EBITDA into a clean run rate; the real test is whether Q3/Q4 show sustainable same-facility margin expansion without another payment tailwind.

Key Decisions for Investors

• Long ACHC on a 3-6 month horizon, but size as an earnings-quality trade rather than a pure growth story; upside is in FCF normalization and de novo ramp, while downside is revenue-cycle slippage.
• Sell downside protection: use ACHC cash-secured puts or put spreads into the next 30-60 days to monetize elevated uncertainty around payer denials and leverage optics.
• Pair trade: long ACHC / short a slower-ramping healthcare-services name with similar multiple but weaker volume momentum; the relative bet is that ACHC’s admissions and bed additions keep compounding faster over the next 2 quarters.
• If ACHC rallies hard on supplemental-payment optimism, fade part of the move via a short-dated call spread; the easiest over-earnings narrative is the temporary Q2 leverage spike and nonrecurring EBITDA support.
• Monitor for a long-entry add only if AR days and cash conversion stabilize by the next quarter; that would confirm revenue-cycle risk is contained and unlock a cleaner rerating.